Astellas Pharma (STU:YPH) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:YPH Astellas Pharma Inc STU:YPH
83 GF Score
Price €11.40
GF Value €12.37
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:YPH vs LLY, JNJ, ABBV: Short Percentage of Float Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Short Percentage of Float falls into.


STU:YPH
83GF Score
Astellas Pharma Inc STU:YPH
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (STU:YPH) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of €11.40 is trading 7.8% below its estimated GF Value™ of €12.37. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for STU:YPH:

  • Short Percentage of Float:
  • GF Value™: €12.37 vs. price of €11.40 (7.8% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the STU:YPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
83GF Score

Get the complete analysis for STU:YPH

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.40
Price
€12.37
GF Value